{"nctId":"NCT01697566","briefTitle":"An Endometrial Cancer Chemoprevention Study of Metformin","startDateStruct":{"date":"2013-05-30","type":"ACTUAL"},"conditions":["Gynecology"],"count":29,"armGroups":[{"label":"Metformin","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin","Procedure: Endometrial Biopsy","Behavioral: Questionnaires"]},{"label":"Placebo + Lifestyle Intervention","type":"EXPERIMENTAL","interventionNames":["Other: Placebo","Procedure: Endometrial Biopsy","Behavioral: Lifestyle Intervention","Behavioral: Questionnaires"]},{"label":"Metformin + Lifestyle Intervention","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin","Procedure: Endometrial Biopsy","Behavioral: Lifestyle Intervention","Behavioral: Questionnaires"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo","Procedure: Endometrial Biopsy","Behavioral: Questionnaires"]}],"interventions":[{"name":"Metformin","otherNames":[]},{"name":"Placebo","otherNames":["sugar pill"]},{"name":"Endometrial Biopsy","otherNames":[]},{"name":"Lifestyle Intervention","otherNames":[]},{"name":"Questionnaires","otherNames":["surveys"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. For this study, only women will be enrolled.\n2. Body Mass Index (BMI) \\> or = 30 kg/m2\n3. Not frankly diabetic, as measured by a fasting blood glucose \\</=126 mg/dL.\n4. Demonstrate hyperinsulinemia with a QUICK I value \\</= 0.357.\n5. Age \\>/= 50 and \\</= 65\n6. Zubrod Performance Scale 0-1\n7. Hemoglobin \\>/= 10 g/dl\n8. TSH 0.27 - 4.20 ÂµlU/mL\n9. Menopause as defined as no menses for 1 year and/or FSH \\>/= 25.8 mIU/ml\n10. Must be able to read, write, and speak English.\n11. Must have a Primary Care Provider (PCP).\n\nExclusion Criteria:\n\n1. Prior hysterectomy or endometrial ablation\n2. ALT \\>/r = 2.0x Upper Limit of Normal (ULN)\n3. Serum creatinine \\> /= 1.4 mg/dl\n4. Triglycerides (fasting) \\>/ = 400\n5. Known inability to participate in the ongoing appointments for the four months of the study and scheduled follow-up tests.\n6. Significant medical or psychiatric history which would make the participant a poor protocol candidate, in the opinion of the principal investigator, for any aspect of study participation including metformin, unsupervised exercise program or dietary behavior change.\n7. Participant reported history of congestive heart failure\n8. Prior treatment with Metformin\n9. Currently being treated for diabetes or meeting criteria for new diagnosis of diabetes.\n10. Known allergy to Metformin or other biguanide (Proguanil).\n11. Use of Aromatase Inhibitors, GNRH-agonists i.e.Lupron, Zoladex within the last 6 months\n12. Use of SERMS (selective estrogen receptor modulators) in the past 6 months, including Tamoxifen and Raloxifene\n13. Hormone replacement therapy within the last 6 months\n14. Women who have been treated with chemotherapy for prior malignant disease or currently have an untreated malignancy other than non-melanoma skin cancer\n15. Patients who have had prior radiation to the pelvis","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"50 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"To Evaluate the Participant Body Weight in Pounds (Lbs)","description":"This study will use a 2 x 2 randomized design with all 100 post- menopausal subjects being randomized to metformin, placebo, placebo and intensive lifestyle intervention, or metformin and intensive lifestyle intervention. Treatments will last 4 months. Participants will be assessed at baseline and end of treatment with endometrial sampling to see if there are changes in the biomarkers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108.57","spread":"22.51"},{"groupId":"OG001","value":"99.3","spread":"15.36"},{"groupId":"OG002","value":"101.64","spread":"13.44"},{"groupId":"OG003","value":"94.1","spread":"12.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101.19","spread":"22.47"},{"groupId":"OG001","value":"96.39","spread":"15.36"},{"groupId":"OG002","value":"97.98","spread":"16.46"},{"groupId":"OG003","value":"94.37","spread":"13.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102.08","spread":"35.32"},{"groupId":"OG001","value":"95.93","spread":"12.63"},{"groupId":"OG002","value":"93.25","spread":"8.15"},{"groupId":"OG003","value":"94.96","spread":"13.68"}]}]}]},{"type":"PRIMARY","title":"To Evaluate the Percentage of Ki-67 Positive Cells","description":"The Q-PCR analyses will be performed in the Quantitative Genomics Core Facility at the University of Texas Medical School at Houston.\n\nOver the last 3 years we have used several techniques including differential display, microchip array screening, and real-time quantitative PCR to find such genes. The tools we have developed are directly applicable to the investigation of surrogate endpoint biomarkers (SEBs). Identification of appropriate biomarkers is essential for this study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.78","spread":"8.29"},{"groupId":"OG001","value":"7.95","spread":"5.13"},{"groupId":"OG002","value":"9.23","spread":"3.96"},{"groupId":"OG003","value":"4.73","spread":"1.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.73","spread":"4.17"},{"groupId":"OG001","value":"4.98","spread":"3.94"},{"groupId":"OG002","value":"4.17","spread":"2.37"},{"groupId":"OG003","value":"9.1","spread":"5.96"}]}]}]},{"type":"SECONDARY","title":"BMI","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.25","spread":"9.36"},{"groupId":"OG001","value":"38.17","spread":"5.18"},{"groupId":"OG002","value":"39.49","spread":"4.71"},{"groupId":"OG003","value":"35.29","spread":"4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.83","spread":"7.82"},{"groupId":"OG001","value":"37.34","spread":"4.78"},{"groupId":"OG002","value":"37.83","spread":"5.53"},{"groupId":"OG003","value":"35.31","spread":"4.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.13","spread":"13.45"},{"groupId":"OG001","value":"37.18","spread":"4.41"},{"groupId":"OG002","value":"36","spread":"2.3"},{"groupId":"OG003","value":"35.54","spread":"4.23"}]}]}]},{"type":"SECONDARY","title":"Weight Loss","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.10","spread":"5.22"},{"groupId":"OG001","value":"-2.95","spread":"2.34"},{"groupId":"OG002","value":"-3.88","spread":"5.11"},{"groupId":"OG003","value":"0.25","spread":"1.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.49","spread":"13.51"},{"groupId":"OG001","value":"-3.09","spread":"3.45"},{"groupId":"OG002","value":"-3.37","spread":"4.92"},{"groupId":"OG003","value":"0.83","spread":"0.95"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":["Flatulence","Headache","Diarrhea","Abdominal pain","Nausea"]}}}